THU0527 Lesinurad, A Selective Uric Acid Reabsorption Inhibitor, in Combination with Xanthane Oxidase Inhibitors: SUA and Flares Composite Endpoint from Phase III Studies in Gout Patients (Clear 1, Clear 2 and Crystal)

Abstract

BackgroundLesinurad (RDEA594) is a selective uric acid reabsorption inhibitor (SURI) investigated for treatment of gout in combination with xanthine oxidase inhibitors (XOI).ObjectivesInvestigate efficacy as assessed by a composite endpoint of...